Trial
KEYNOTE-006
Randomized trial of pembrolizumab versus ipilimumab in advanced melanoma.
Also called: KEYNOTE-006, pembrolizumab vs ipilimumab melanoma
In short
- 1What it is: a trial in therapies and applications.
- 2How it connects: acts on 1 and is affected by 1 concepts — mostly 2 therapy.
- 3Where it sits: trial on the 15-step immune chain.
What it does
N=834; pembrolizumab vs ipilimumab in advanced melanoma; 5yr OS: 38.7% vs 31.1% (p<0.001); irAE grade 3-4: 17% vs 27%; showed the PD-1 axis outperformed the CTLA-4 axis in melanoma; established anti-PD-1 as first-line for all PD-L1+ advanced cancers
Its connections at a glance
Each dot is a concept directly linked to KEYNOTE-006. Colours show the kind of concept.
Sources & evidenceloading…
Loading reviewed sources…
Graph ID TR003 · concept status: established. Select any connection above to inspect evidence for that specific link.